BIORETEC

08/13/2026 21:38 EEST

This is a translated version of the "Kasvua on, trendi ei vielä erotu" report, published on 08/14/2026

Antti Siltanen, Analyst
+358 45 119 6869
antti.siltanen@inderes.fi

INDERES CORPORATE CUSTOMER

COMPANY REPORT

There is growth, but the trend is not yet clear

Bioretec's revenue in early 2026 continued its positive development from the comparison period, but profitability fell short of our estimate. However, growth stabilized in Q2 compared to the previous quarter. Geographically, the strongest development was seen in the US (+134% vs Q2'25). The profitability undershoot relative to our estimate was due to sales representative model costs, which increased more than we expected. Regarding our estimates, we left our revenue estimates unchanged, but decreased our earnings estimates due to higher costs. Following the estimate changes, we revise our target price to EUR 0.024 (was EUR 0.026). We feel the risk/reward ratio remains unsatisfactory after the share price increase and estimate changes, so we downgrade our recommendation to Reduce (was Accumulate).

Revenue grew briskly from the weak comparison period

Q2 revenue grew organically by 62% year-on-year to 1.10 MEUR, slightly below our 1.20 MEUR estimate. Growth came from all regions: Europe grew by 64%, the US by 134%, and the rest of the world by 34%. According to the company, growth was generated by an expanded customer and distributor network, as well as higher volumes. RemeOs sales are still not reported separately, making it difficult to assess the commercial progress of the product family. Absolute volumes are still small, so individual distributor orders can cause significant volatility in the figures from one quarter to another. Revenue decreased from Q1's 1.22 MEUR, meaning that the development of consecutive quarters does not yet support the interpretation of a continuous growth trend.

Costs exceeded our estimates

The Q2 EBIT was -2.31 MEUR (Q2'25: -3.37 MEUR) and clearly missed our -1.75 MEUR estimate. The comparison period's result included a non-recurring expense of 1.1 MEUR due to the repurchase of inventories. Considering this, operating expenses increased by 9% from the comparison period. Three factors explain the difference between the actual result and our estimate: 1) the level of revenue, 2) seasonally higher personnel expenses than we expected, and 3) a lower gross margin than we expected, which we believe is due to the costs of the sales representative model. The change negotiations concluded in June will bring annual savings of 0.2 MEUR on top of the previous 0.4 MEUR.

Growth estimates unchanged - earnings expectations cut

We keep our revenue estimates for the coming years unchanged, as revenue fluctuations from quarter to quarter are still quite large, and the recent report does not change our view on the likely growth trajectory. We are making a more significant cut to our EBIT estimate for 2026–28, as our previous assessment of sales representative model costs proved overly optimistic. The report offered few concrete figures on the structural growth of sales, so visibility into the company's business development is low even in the short term. We look forward to future quarters and information on sales development, as well as new indications and product launches.

The share has potential, but risks currently outweigh it

EV/S multiples on our 2026-27 estimates are 4.7-4.0x. We find the multiples moderate in absolute terms, but not particularly low across the board compared to the cheaper peer companies. Based on our DCF model, there stock has no significant upside. We believe the share has a lot of potential if revenue develops faster than our estimates. On the other hand, potentially slow progress combined with unprofitability keeps the risk level very high. Currently, visibility into the future pace of growth and thus the turnaround in cash flows is still low, and we find the share's risk/reward ratio unsatisfactory for the time being.

Recommendation

Reduce

(was Accumulate)

Target price:

EUR 0.024

(was EUR 0.026)

Share price:

EUR 0.023

Business risk

●●●●●

Valuation risk

●●●○○

	2025	2026e	2027e	2028e
Revenue	3.5	5.1	7.7	11.1
Growth-%	-22 %	44 %	52 %	44 %
EBIT adj.	-8.7	-8.0	-6.0	-3.9
Net profit	-9.5	-8.7	-6.5	-4.6
EPS (adj.)	-0.31	-0.01	0.00	0.00
P/E (adj.)	neg.	neg.	neg.	neg.
P/B	1.9	2.2	4.2	11.0
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %
EV/EBIT (adj.)	neg.	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.	neg.
EV/Sales	4.6	4.7	4.0	3.3

Source: Inderes

Guidance

The company does not provide any guidance

Share price



Source: Millistream Market Data AB

Revenue and EBIT % (adj.)



Source: Inderes

Value drivers

- RemeOs products bring new solutions and added value to the healthcare system and patients
- The first viable player in the key US market for absorbable metallic implants
- Potential for strong long-term growth and robust profitability in a defensive industry
- Growth through indication expansion, geographical expansion, and new products

Risk factors

- A market breakthrough with new technology is uncertain and likely slow
- Due to investment needs and unprofitability, profitability is still a few years away, even in the best-case scenario
- The financial risk is high, and the possibility of losing capital is concrete if growth targets are not met

Valuation	2026e	2027e	2028e
Share price	0.023	0.023	0.023
Number of shares, millions	1341.8	1341.8	1341.8
Market cap	31	31	31
EV	24	31	37
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/B	2.2	4.2	11.0
P/S	6.1	4.0	2.8
EV/Sales	4.7	4.0	3.3
EV/EBITDA	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

Revenue grew briskly from the weak comparison period

Revenue was roughly in line with our expectations

Bioretec's Q2 revenue of 1.10 MEUR, falling short of our 1.20 MEUR estimate by 0.10 MEUR, or ~8%. The deviation is small in absolute terms, and we believe the quarter was a neutral performance in terms of revenue. Regionally, Europe (0.35 MEUR) grew by 64%, the rest of the world (0.45 MEUR) by 34%, and the US (0.31 MEUR) by 134% year-on-year. Absolute volumes are still small, so individual distributor orders can cause significant volatility in the figures from one quarter to another. According to Bioretec, the growth is explained by stable volume growth and the expansion of the customer base, which indicates a structural improvement. However, revenue decreased from the previous quarter. The growth rate thus remains uncertain for now, especially as the company does not report RemeOs sales separately.

Our earnings estimate was overoptimistic

Q2 EBIT of -2.31 MEUR was clearly below our estimate of -1.75 MEUR. Part of the deviation is explained by revenue, and the majority came from the expense side. In particular, the reported gross profit was lower than our expectations. In our view, the costs of the US sales representative model decrease the reported gross margin, and our estimates in this regard were overly optimistic. Personnel costs in Q2 were also higher than we expected, which we believe is at least partly due to seasonal bonuses. The adjusted gross margin was 68.0% (excluding the aforementioned sales expenses). The company's strategy period target is an adjusted margin of over 70%.

Cash is sufficient until Q3'27

At the end of June, the company's cash and cash equivalents were 12.0 MEUR (Q2'25 11.5 MEUR) and interest-bearing liabilities only 0.2 MEUR. H1 cash flow from operating activities was -3.81 MEUR and investments were 0.20 MEUR, meaning free cash flow was around -4.0 MEUR from -4.1 MEUR in the comparison period. Working capital commitment was 0.15 MEUR, which is clearly less than in the latter half of last year.

After the 12.9 MEUR share issue in April, the funding is sufficient, according to the company and our estimates, until Q3'27, meaning the next funding round will likely occur in H1'27. The next funding round could be the company's last if business develops favorably. However, we believe investors should also be prepared for the possibility of a second financing round in the medium term.

Estimates MEUR / EUR	Q2'25 Comparison	Q2'26 Actualized	Q2'26e Inderes	2026e Inderes
Revenue	0.68	1.10	1.20	5.09
EBITDA	-3.32	-2.25	-1.65	-7.58
EBIT	-3.36	-2.31	-1.75	-7.98
EPS (reported)	-0.14	0.00	0.00	-0.01
Revenue growth-%	-50.8 %	62.2 %	77.0 %	44.4 %

Source: Inderes

Bioretec H1'26: Expansion of the product portfolio into spinal applications progresses

Growth estimates unchanged - earnings expectations cut

Estimate revisions

- Our revenue estimates for the coming years remain practically unchanged.
- In terms of growth, the report was roughly in line with our expectations, and the visibility to the future is rather low. Thus, we see no reason to adjust our growth expectations based on the report.
- Our growth estimates are moderate but still require continuous positive business development.
- Our earnings estimates for the coming years are decreasing due to our higher expectations for the cost of sales.
- Sales representatives receive a commission on the products they sell. Bioretec does not report the cost of sales separately in its income statement, and the level of expenses was a surprise to us in this report.
- Cash and cash equivalents amounted to 12 MEUR at the end of Q2, which the company expects to be sufficient until Q3'27.

Estimate revisions MEUR / EUR	2026e Old	2026e New	Change %	2027e Old	2027e New	Change %	2028e Old	2028e New	Change %
Revenue	5.2	5.1	-2%	7.7	7.7	0%	11.1	11.1	0%
EBITDA	-6.4	-7.6	-19%	-4.0	-5.2	-29%	-2.2	-3.2	-50%
EBIT (exc. NRIs)	-6.8	-8.0	-17%	-4.8	-6.0	-24%	-2.8	-3.9	-39%
EBIT	-6.8	-8.0	-17%	-4.8	-6.0	-24%	-2.8	-3.9	-39%
PTP	-7.8	-9.0	-15%	-5.4	-6.5	-22%	-3.4	-4.6	-35%
EPS (excl. NRIs)	-0.01	-0.01	-16%	0.00	0.00	-22%	0.00	0.00	-35%
DPS	0.00	0.00		0.00	0.00		0.00	0.00	

Source: Inderes

Risks now weigh more heavily in the balance

Risk/reward has weakened

We are lowering our recommendation and target price as the share price increase since the previous update and decreased earnings estimates have weakened the risk/reward We believe Bioretec has implemented the right corrective actions for its business and strengthened key weaknesses, especially in sales. Early examples of the impact of the changes have been seen, but visibility for the future is still low, and uncertainty is high. We expect growth will materialize gradually, which is typical for the industry, but if successful, it will likely also gradually restore damaged investor confidence and thus normalize the company's situation. We consider the next financing round during H1'27 to be quite likely, and we believe investors should also be prepared for the possibility of a second financing round in the medium term.

Uncertainties in valuation and estimates

Because of the loss-making business, we cannot use earnings-based multiples in valuation but instead rely on revenue-based EV/S ratios and DCF calculation that models the present value of future cash flows. The valuation is inherently imprecise as it is based on forecasts with little visibility, although we believe the situation has improved.

DCF model indicates EUR 0.024

Our DCF model's baseline scenario indicates a per-share value of future cash flows of EUR 0.024. The calculation relies heavily on long-term growth and cash flows, with the coming years remaining clearly unprofitable. We assume terminal growth of 2% and EBIT of 20% of revenue, reflecting the good profitability of the industry's companies in a mature development phase.

The high-growth DCF scenario relies on the assumption that a large international medical device manufacturer would acquire Bioretec's product portfolio and rapidly commercialize RemeOs™ products utilizing its own international sales and distribution organization. In this scenario, we assume revenue to be 25% above the baseline scenario and the EBIT margin to be higher (TERM EBIT 25%) due to efficient sales and distribution. This scenario gives the share a value of around EUR 0.9. Our low-growth DCF scenario is based on 50% lower growth compared to the baseline scenario and generates a share value of EUR 0.005. The calculation refers to the risk of permanent loss of capital should the company fail to commercialize the RemeOs™ product line.

Investors should note that there are considerable uncertainties about the realization of estimated cash flows. The DCF model is also very sensitive to the assumptions used, especially when cash flows are far in the future. The cost of capital (WACC) used in the DCF model is 13%, reflecting our stance on the share's high risk level.

EV/S ratios are neutral

Bioretec's EV/S ratio with our 2026 estimates is 4.7x and decreases to 40x in the following year. The multiples have increased but are still relatively moderate compared to the growth and profitability potential. This is largely justified in the current situation, as the company's track record of growth is still limited. We estimate Bioretec's fair EV/S multiple range in a normal scenario to be 6x-10x, though this requires achieving consistent, defensive, and rapid growth from a low starting point. The multiples of peer companies have fallen below Bioretec's multiples, which we do not consider justified.

Valuation	2026e	2027e	2028e
Share price	0.023	0.023	0.023
Number of shares, millions	1341.8	1341.8	1341.8
Market cap	31	31	31
EV	24	31	37
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/B	2.2	4.2	11.0
P/S	6.1	4.0	2.8
EV/Sales	4.7	4.0	3.3
EV/EBITDA	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

Valuation table

Valuation	2021	2022	2023	2024	2025	2026e	2027e	2028e	2029e
Share price	2.70	1.40	2.18	2.40	0.60	**0.02**	**0.02**	**0.02**	**0.02**
Number of shares, millions	14.1	14.1	19.1	23.3	30.8	**1341.8**	**1341.8**	**1341.8**	**1341.8**
Market cap	38	20	42	56	18	**31**	**31**	**31**	**31**
EV	33	20	37	51	16	**24**	**31**	**37**	**38**
P/E (adj.)	neg.	neg.	neg.	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
P/E	neg.	neg.	neg.	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
P/B	8.8	10.3	5.1	5.8	1.9	**2.2**	**4.2**	**11.0**	**18.1**
P/S	19.0	6.7	10.7	12.3	5.2	**6.1**	**4.0**	**2.8**	**2.2**
EV/Sales	16.7	6.8	9.5	11.3	4.6	**4.7**	**4.0**	**3.3**	**2.6**
EV/EBITDA	neg.	neg.	neg.	neg.	neg.	**neg.**	**neg.**	**neg.**	**>100**
EV/EBIT (adj.)	neg.	neg.	neg.	neg.	neg.	**neg.**	**neg.**	**neg.**	**neg.**
Payout ratio (%)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	**0.0 %**	**0.0 %**	**0.0 %**	**0.0 %**
Dividend yield-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	**0.0 %**	**0.0 %**	**0.0 %**	**0.0 %**

Source: Inderes

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years.

Peer group valuation

Peer group valuation	Market cap	EV	EV/EBIT		EV/EBITDA		EV/S		P/E		Dividend yield-%		P/B
Company	**MEUR**	**MEUR**	**2026e**	**2027e**	**2026e**	**2027e**	**2026e**	**2027e**	**2026e**	**2027e**	**2026e**	**2027e**	**2026e**
Ambu A/S	2,666	2,647	24.4	18.6	16.8	13.6	3.1	2.8	32.0	23.8	0.6	0.9	3.1
Bonesupport AB	1,372	1,333	36.1	22.3	34.4	21.7	9.8	7.5	48.0	29.9	0.3	0.5	12.9
C Rad AB	107	95	13.3	10.6	11.4	9.3	2.3	2.0	15.7	15.2	1.3	1.8	3.0
Elekta AB	1,751	2,118	12.8	10.7	7.5	6.8	1.4	1.4	16.2	13.7	4.5	4.8	2.3
Getinge AB	5,919	6,747	15.1	13.9	10.8	10.0	2.1	2.0	19.3	17.6	2.2	2.4	2.1
Medistim ASA	382	368	20.6	18.6	18.0	16.3	5.3	4.9	30.2	27.1	2.7	2.9	8.3
Optomed Plc	38	32				60.9	1.8	1.5					1.8
Vitrolife AB	1,111	1,182	18.4	16.1	11.7	10.7	3.8	3.5	25.1	20.7	1.2	1.3	1.5
Xvivo Perfusion AB	879	862	78.8	39.2	46.1	26.6	9.6	7.5	100.4	50.5			4.6
Sedana	101	97				34.6	5.1	3.9		562.0			1.3
Ossdsign AB	42	26					1.7	1.2					1.8
Kuros Biosciences	974	962	57.8	29.3	47.4	26.2	5.1	4.0	106.6	52.1			10.3
Bioretec (Inderes)	**31**	**24**	**-3.0**	**-5.2**	**-3.2**	**-6.0**	**4.7**	**4.0**	**-3.6**	**-4.8**	**0.0**	**0.0**	**2.2**
Average			**30.8**	**19.9**	**22.7**	**21.5**	**4.2**	**3.5**	**43.7**	**81.3**	**1.8**	**2.1**	**4.4**
Median			**20.6**	**18.6**	**16.8**	**16.3**	**3.4**	**3.1**	**30.2**	**25.5**	**1.3**	**1.8**	**2.7**
Diff-% to median			***-115%***	***-128%***	***-119%***	***-137%***	***39%***	***29%***	***-112%***	***-119%***	***-100%***	***-100%***	***-16%***

Source: Refinitiv / Inderes

Income statement

Income statement	2024	2025	Q1'26	Q2'26	Q3'26e	Q4'26e	2026e	2027e	2028e	2029e
Revenue	**4.5**	**3.5**	**1.2**	**1.1**	**1.2**	**1.6**	**5.1**	**7.7**	**11.1**	**14.4**
EBITDA	**-4.1**	**-8.5**	**-1.3**	**-2.2**	**-2.1**	**-2.0**	**-7.6**	**-5.2**	**-3.2**	**0.4**
Depreciation	-0.1	-0.2	-0.1	-0.1	-0.1	-0.1	-0.4	-0.8	-0.6	-0.6
EBIT	**-4.2**	**-8.7**	**-1.4**	**-2.3**	**-2.2**	**-2.1**	**-8.0**	**-6.0**	**-3.9**	**-0.3**
Net financial items	-0.4	-1.2	0.0	-1.0	0.0	0.0	-1.0	-0.6	-0.7	-0.8
PTP	**-4.6**	**-9.9**	**-1.4**	**-3.3**	**-2.2**	**-2.1**	**-9.0**	**-6.5**	**-4.6**	**-1.1**
Taxes	0.0	0.4	0.0	0.2	0.0	0.2	0.4	0.0	0.0	0.0
Net earnings	**-4.6**	**-9.5**	**-1.4**	**-3.1**	**-2.2**	**-1.9**	**-8.6**	**-6.5**	**-4.6**	**-1.1**
EPS (rep.)	**-0.20**	**-0.31**	**0.00**	**0.00**	**0.00**	**0.00**	**-0.01**	**0.00**	**0.00**	**0.00**

Key figures	2024	2025	Q1'26	Q2'26	Q3'26e	Q4'26e	2026e	2027e	2028e	2029e
Revenue growth-%	16.3 %	-22.5 %	-12.6 %	62.2 %	67.8 %	113.7 %	44.4 %	52.1 %	43.8 %	29.6 %
Adjusted EBIT growth-%	-38.5 %	-106.7 %	-10.6 %	31.3 %	-18.9 %	6.2 %	8.1 %	25.0 %	35.0 %	93.0 %
EBITDA-%	-89.2 %	-240.7 %	-109.4 %	-201.0 %	-172.2 %	-125.6 %	-149.0 %	-67.3 %	-29.2 %	2.4 %
Adjusted EBIT-%	-92.5 %	-246.6 %	-117.6 %	-210.1 %	-180.6 %	-131.9 %	-156.9 %	-77.4 %	-35.0 %	-1.9 %
Net earnings-%	-101.3 %	-269.3 %	-117.6 %	-282.8 %	-180.6 %	-119.2 %	-168.7 %	-84.7 %	-41.2 %	-7.7 %

Source: Inderes

Full-year earnings per share are calculated using the number of shares at year-end.

Balance sheet

Assets	2024	2025	2026e	2027e	2028e
Non-current assets	**1.7**	**2.5**	**2.3**	**2.1**	**2.1**
Goodwill	0.0	0.0	0.0	0.0	0.0
Intangible assets	0.6	1.0	1.3	1.3	1.4
Tangible assets	1.1	1.1	1.1	0.8	0.7
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	0.0	0.4	0.0	0.0	0.0
Current assets	**9.8**	**9.2**	**12.3**	**7.0**	**6.8**
Inventories	1.5	3.9	3.1	3.5	3.9
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	2.0	1.2	1.5	1.9	2.2
Cash and equivalents	6.3	4.1	7.8	1.5	0.7
Balance sheet total	**11.5**	**11.7**	**14.7**	**9.0**	**8.9**

Source: Inderes

Liabilities & equity	2024	2025	2026e	2027e	2028e
Equity	**9.7**	**9.8**	**14.0**	**7.4**	**2.8**
Share capital	3.7	3.7	3.7	3.7	3.7
Retained earnings	-19.8	-29.3	-38.0	-44.6	-49.2
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	25.8	35.3	48.2	48.2	48.2
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	**0.4**	**0.1**	**0.4**	**1.1**	**5.0**
Deferred tax liabilities	0.0	0.0	0.0	0.0	0.0
Provisions	0.0	0.0	0.0	0.0	0.0
Interest bearing debt	0.4	0.1	0.4	1.1	5.0
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.0	0.0	0.0
Current liabilities	**1.0**	**1.8**	**0.3**	**0.5**	**1.1**
Interest bearing debt	1.0	1.8	0.3	0.5	1.1
Payables	0.0	0.0	0.0	0.0	0.0
Other current liabilities	0.0	0.0	0.0	0.0	0.0
Balance sheet total	**11.2**	**11.7**	**14.7**	**9.0**	**8.9**

DCF-calculation

DCF model	2025	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	TERM
Revenue growth-%	-22.5 %	44.4 %	52.1 %	43.8 %	29.6 %	29.3 %	27.7 %	18.0 %	14.0 %	10.0 %	6.0 %	3.0 %	8.0 %	2.0 %
EBIT-%	-246.6 %	-156.9 %	-77.4 %	-35.0 %	-1.9 %	12.0 %	16.0 %	20.0 %	20.0 %	20.0 %	20.0 %	20.0 %	20.0 %	20.0 %
EBIT (operating profit)	**-8.7**	**-8.0**	**-6.0**	**-3.9**	**-0.3**	**2.2**	**3.8**	**5.6**	**6.4**	**7.0**	**7.5**	**7.7**	**8.3**	
+ Depreciation	0.2	0.4	0.8	0.6	0.6	0.7	0.8	0.9	1.1	1.1	1.2	1.2	1.3	
- Paid taxes	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Tax, financial expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
+ Tax, financial income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Change in working capital	-1.6	0.5	-0.8	-0.7	0.1	-0.1	0.0	0.3	0.8	-0.5	-0.3	-0.2	-0.5	
Operating cash flow	**-10.2**	**-6.5**	**-6.0**	**-4.0**	**0.4**	**2.9**	**4.6**	**6.8**	**8.3**	**7.7**	**8.3**	**8.8**	**9.1**	
+ Change in other long-term liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
- Gross CAPEX	-0.5	-0.7	-0.5	-0.7	-0.8	-0.9	-1.1	-1.4	-1.2	-1.1	-1.4	-1.4	-1.4	
Free operating cash flow	**-10.7**	**-7.2**	**-6.6**	**-4.6**	**-0.4**	**2.0**	**3.4**	**5.4**	**7.0**	**6.6**	**6.9**	**7.4**	**7.7**	
+/- Other	9.2	12.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
FCFF	-1.5	5.7	-6.6	-4.6	-0.4	2.0	3.4	5.4	7.0	6.6	6.9	7.4	7.7	73.5
Discounted FCFF		**5.4**	**-5.6**	**-3.5**	**-0.2**	**1.2**	**1.8**	**2.5**	**2.9**	**2.4**	**2.2**	**2.1**	**1.9**	**16.3**
Sum of FCFF present value		31.1	25.6	31.2	34.6	34.9	33.7	31.9	29.4	26.6	24.2	22.0	19.9	16.3
Enterprise value DCF		**31.1**												
- Interest bearing debt		-1.9												
+ Cash and cash equivalents		4.1												
+ Associated companies		0.0												
-Minorities		0.0												
-Dividend/capital return		0.0												
Equity value DCF		**33.3**												
Equity value DCF per share		**0.025**												

WACC	
Tax-% (WACC)	20.0 %
Target debt ratio (D/(D+E)	10.0 %
Cost of debt	10.0 %
Equity Beta	2.00
Market risk premium	4.75%
Liquidity premium	1.50%
Risk free interest rate	2.5 %
Cost of equity	**13.5 %**
Weighted average cost of capital (WACC)	**13.0 %**

Source: Inderes



DCF sensitivity calculations and key assumptions in graphs









Source: Inderes. NB! The terminal value weight (%) is presented on a reverse scale for clarity.

Summary

Income statement	2023	2024	2025	2026e	2027e
Revenue	3.9	4.5	3.5	5.1	7.7
EBITDA	-2.8	-4.1	-8.5	-7.6	-5.2
EBIT	-3.0	-4.2	-8.7	-8.0	-6.0
PTP	-3.8	-4.6	-9.9	-8.9	-6.5
Net Income	-3.8	-4.6	-9.5	-8.7	-6.5
Extraordinary items	0.0	0.0	0.0	0.0	0.0

Balance sheet	2023	2024	2025	2026e	2027e
Balance sheet total	10.7	11.5	11.7	14.7	9.0
Equity capital	8.2	9.7	9.8	14.0	7.4
Goodwill	0.0	0.0	0.0	0.0	0.0
Net debt	-4.5	-4.8	-2.2	-7.1	0.1

Cash flow	2023	2024	2025	2026e	2027e
EBITDA	-2.8	-4.1	-8.5	-7.6	-5.2
Change in working capital	-1.1	-1.0	-1.6	0.5	-0.8
Operating cash flow	-4.0	-5.0	-10.2	-6.5	-6.0
CAPEX	-0.5	-0.6	-0.5	-0.7	-0.5
Free cash flow	4.7	0.0	-1.5	5.7	-6.6

Valuation multiples	2023	2024	2025	2026e	2027e
EV/S	9.5	11.3	4.6	4.7	4.0
EV/EBITDA	neg.	neg.	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.	neg.	neg.
P/E (adj.)	neg.	neg.	neg.	neg.	neg.
P/B	5.1	5.8	1.9	2.2	4.2
Dividend-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %

Source: Inderes

Per share data	2023	2024	2025	2026e	2027e
EPS (reported)	-0.20	-0.20	-0.31	-0.01	0.00
EPS (adj.)	-0.20	-0.20	-0.31	-0.01	0.00
OCF / share	-0.21	-0.22	-0.33	0.00	0.00
OFCF / share	0.24	0.00	-0.05	0.00	0.00
Book value / share	0.43	0.42	0.32	0.01	0.01
Dividend / share	0.00	0.00	0.00	0.00	0.00

Growth and profitability	2023	2024	2025	2026e	2027e
Revenue growth-%	33%	16%	-22%	44%	52%
EBITDA growth-%	-42%	-43%	-109%	11%	31%
EBIT (adj.) growth-%	-32%	-38%	-107%	8%	25%
EPS (adj.) growth-%	-15%	0%	-56%	98%	25%
EBITDA-%	-72.6 %	-89.2 %	-240.7 %	-149.0 %	-67.3 %
EBIT (adj.)-%	-77.7 %	-92.5 %	-246.6 %	-156.9 %	-77.4 %
EBIT-%	-77.7 %	-92.5 %	-246.6 %	-156.9 %	-77.4 %
ROE-%	-74.7 %	-51.2 %	-97.2 %	-73.4 %	-61.3 %
ROI-%	-42.9 %	-38.4 %	-75.9 %	-60.6 %	-54.8 %
Equity ratio	77.2 %	84.8 %	83.6 %	95.2 %	81.9 %
Gearing	-54.5 %	-49.5 %	-22.6 %	-50.5 %	1.2 %
Net debt/EBITDA	1.6	1.2	0.3	0.9	0.0
EBITDA/net financials	-3.8	-10.2	-7.1	-8.6	-9.3

The market cap and enterprise value in the table consider the expected change in the number of shares and net debt for the forecast years. Per-share figures are calculated using the number of shares at year-end.

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy	The 12-month risk-adjusted expected shareholder return of the share is very attractive
Accumulate	The 12-month risk-adjusted expected shareholder return of the share is attractive
Reduce	The 12-month risk-adjusted expected shareholder return of the share is weak
Sell	The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

Date	Recommendation	Target	Share price
9/23/2022	Reduce	1.60 €	1.86 €
10/17/2022	Reduce	1.40 €	1.40 €
2/20/2023	Sell	1.90 €	3.04 €
4/1/2023	Sell	2.40 €	3.26 €
5/1/2023	Accumulate	2.70 €	2.25 €
8/14/2023	Accumulate	2.90 €	2.50 €
12/27/2023	Buy	2.80 €	2.18 €
2/19/2024	Accumulate	2.80 €	2.34 €
5/3/2024	Accumulate	3.00 €	2.50 €
5/17/2024	Accumulate	3.00 €	2.65 €
8/16/2024	Reduce	2.90 €	2.90 €
10/8/2024	Reduce	2.60 €	2.38 €
11/15/2024	Accumulate	2.40 €	1.94 €
2/17/2025	Accumulate	2.80 €	2.47 €
5/16/2025	Accumulate	2.80 €	2.30 €
5/30/2025	Accumulate	2.40 €	1.90 €
6/24/2025	Buy	2.40 €	1.70 €
8/15/2025	Accumulate	1.70 €	1.40 €
10/29/2025	Accumulate	1.20 €	0.91 €
11/14/2025	Accumulate	1.05 €	0.85 €
12/7/2026	Reduce	0.60 €	0.68 €
2/16/2026	Accumulate	0.32 €	0.27 €
3/30/2026	Accumulate	0.018 €	0.013 €
4/29/2026	Accumulate	0.018 €	0.014 €
5/18/2026	Accumulate	0.021 €	0.017 €
6/25/2026	Accumulate	0.026 €	0.021 €
8/14/2026	Reduce	0.024 €	0.023 €



CONNECTING INVESTORS AND COMPANIES.

Inderes connects investors and listed companies.

We serve over 400 Nordic listed companies that want to better serve investors. The Inderes community is home to over 70,000 active investors.

We provide listed companies with solutions that enable seamless and effective investor relations. The Inderes service is built on four cornerstones for high-quality investor relations: Equity Research, Events, IR Software, and Annual General Meetings (AGM).

Inderes operates in Finland, Sweden, Norway, and Denmark and is listed on the Nasdaq First North Growth Market.

Inderes was created by investors, for investors.

Inderes Ab
Vattugatan 17, 5tr
Stockholm
+46 8 411 43 80

inderes.se

Inderes Oyj
Porkkalankatu 5
00180 Helsinki
+358 10 219 4690

inderes.fi

inde
res.